Checked
Amgen Inc
Nasdaq: AMGN · Biological Products, (No Diagnostic Substances) · Thousand Oaks, CA
- Revenue
- $36.75B
- +10.0% vs. prior year
- Net income
- $7.71B
- 21.0% net margin
- Total assets
- $90.59B
- Diluted EPS
- $14.23
Company details
As reported to the SEC
- SEC CIK
- 318154
- Stock
- Nasdaq: AMGN
- Legal Entity Identifier (LEI)
- 62QBXGPJ34PQ72Z12S66
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- One Amgen Center Drive, Thousand Oaks, CA 91320
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Phone
- (805) 447-1000
- Employer ID (EIN)
- 95-3540776
- Last annual report
- 02/13/2026
- Last quarterly report
- 08/05/2026
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B |
| Operating income | $9.08B | $7.26B | $7.9B | $9.57B | $7.64B |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B |
| Diluted earnings per share | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 |
| Research and development | $7.27B | $5.96B | $4.78B | $4.43B | $4.82B |
| Total assets | $90.59B | $91.84B | $97.15B | $65.12B | $61.16B |
| Shareholders' equity | $8.66B | $5.88B | $6.23B | $3.66B | $6.7B |
| Cash and cash equivalents | $9.13B | $11.97B | $10.94B | $7.63B | $7.99B |
| Long-term debt | $50.01B | $56.55B | $63.17B | $37.35B | $33.22B |
| Cash from operations | $9.96B | $11.49B | $8.47B | $9.72B | $9.26B |
| Capital expenditures | $1.86B | $1.1B | $1.11B | $936M | $880M |
Federal and state records filed under the name Amgen Inc
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Amgen Inc.Thousand Oaks, CA | 311 | 101 |
| Horizon Therapeutics USA, Inc.Subsidiary · Deerfield, IL | 7 | 0 |
| Horizon Therapeutics Services LLCSubsidiary · Deerfield, IL | 1 | 0 |
FDA recalls
Latest 10 of 12 recalls of food, drugs and devices
Swipe the table sideways to see more columns.
Drug shortages
Products this company makes or markets that are on the FDA drug shortage list
| Drug | Status |
|---|---|
| Glycerol Phenylbutyrate Oral Liquid | To Be Discontinued |
| Ivabradine Hydrochloride Tablet | To Be Discontinued |
| Ivabradine Solution | To Be Discontinued |
Trucking registrations
Motor carrier registrations with the Federal Motor Carrier Safety Administration
Swipe the table sideways to see more columns.
| Carrier | USDOT | Power units |
|---|---|---|
| Amgen IncThousand Oaks, CA | 921609 | 18 |
| Immunex Rhode Island CorpSubsidiary · West Greenwich, RI | 1160990 | 1 |
Subsidiaries
39 companies that Amgen Inc owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Amgen (Europe) GmbH | SEC 10-K |
| Amgen Canada Inc. | SEC 10-K |
| Amgen Fremont Inc. | SEC 10-K |
| Amgen Global Finance B.V. | GLEIF, SEC 10-K |
| Amgen Global Technology Unlimited Company | SEC 10-K |
| Amgen GmbH Germany | SEC 10-K |
| Amgen K-A, Inc. | SEC 10-K |
| Amgen K.K. | SEC 10-K |
| Amgen Manufacturing Limited LLC | SEC 10-K |
| Amgen Rare Disease Holdings Inc. | SEC 10-K |
| Amgen Research (Munich) GmbH | SEC 10-K |
| Amgen S.A.S. | SEC 10-K |
| Amgen S.p.A. | SEC 10-K |
| Amgen SF, LLC | SEC 10-K |
| Amgen Singapore Holding Pte. Ltd. | SEC 10-K |
| Amgen Singapore Manufacturing Pte. Ltd. | SEC 10-K |
| Amgen Technology (Ireland) Unlimited Company | SEC 10-K |
| Amgen Technology, Limited | SEC 10-K |
| Amgen USA Inc. | SEC 10-K |
| Amgen Worldwide Holdings B.V. | SEC 10-K |
| Amgen, S.A. | SEC 10-K |
| BioVex LLC | SEC 10-K |
| ChemoCentryx, Inc. | SEC 10-K |
| Five Prime Therapeutics, Inc. | SEC 10-K |
| HZNP Finance Limited | SEC 10-K |
| Horizon Therapeutics Finance S.à.r.l | SEC 10-K |
| Horizon Therapeutics Holdings Limited | SEC 10-K |
| Horizon Therapeutics Ireland DAC | SEC 10-K |
| Horizon Therapeutics Services LLC | SEC 10-K |
| Horizon Therapeutics U.S. Holding LLC | SEC 10-K |
| Horizon Therapeutics USA, Inc. | SEC 10-K |
| Immunex Corporation | SEC 10-K |
| Immunex Rhode Island Corporation | SEC 10-K |
| Onyx Pharmaceuticals, Inc. | SEC 10-K |
| Onyx Therapeutics, Inc. | SEC 10-K |
| Pillartree Limited | SEC 10-K |
| Saga Investments Coöperatief U.A. | SEC 10-K |
| TeneoBio, Inc. | SEC 10-K |
| Viela Bio, Inc. | SEC 10-K |
Recent filings
112 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
98 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Amgen Inc in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
| BIO-TECHNE CorpTECH | Minneapolis, MN | $1.22B | $181.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Amgen Inc's CIK number?
- Amgen Inc's SEC Central Index Key (CIK) is 318154.
- What is Amgen Inc's stock ticker?
- Amgen Inc trades as Nasdaq: AMGN.
- What was Amgen Inc's revenue?
- Amgen Inc reported revenue of $36.75B for the fiscal year ended Dec 31, 2025, +10.0% from the year before.
- When does Amgen Inc's fiscal year end?
- Amgen Inc's fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Amgen Inc headquartered?
- Amgen Inc's principal executive office on file with the SEC is in Thousand Oaks, CA.
- What companies does Amgen Inc own?
- Amgen Inc lists 39 subsidiaries in its SEC filings and other public records, including Amgen (Europe) GmbH, Amgen Canada Inc., Amgen Fremont Inc.
- Does Amgen Inc sponsor H-1B visas?
- Department of Labor records show 319 certified H-1B filings and 101 certified PERM filings under the name Amgen Inc.
- Has Amgen Inc had any FDA recalls?
- The FDA lists 12 recalls with Amgen Inc as the recalling firm. The latest started Jun 4, 2026.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026